Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating nrp2-associated diseases

A technology for treating compositions and diseases, applied in the field of compositions and methods for treating NRP2-related diseases

Pending Publication Date: 2021-03-16
ATYR PHARM INC
View PDF105 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the role of Jo-1 antibodies in disease progression is unclear, subjects with Jo-1 antibodies tend to be less likely to develop cancer than subjects with inflammatory myopathies who do not have Jo-1 antibodies (See eg Lu et al., PLOS ONE 9(4)e94128, 2014; Modan et al., Clin. Exp. Dermatol. 34(5) 561-565, 2009; and Shi et al., J.Rheum 44(7) doi10.3899 / jrheum.161480)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating nrp2-associated diseases
  • Compositions and methods for treating nrp2-associated diseases
  • Compositions and methods for treating nrp2-associated diseases

Examples

Experimental program
Comparison scheme
Effect test

example

[0682] Materials and methods

[0683] ELISA assay

[0684] Assays for measuring circulating human and mouse endogenous HRS An ELISA detection assay was developed to detect circulating small The levels of murine or human HRS were quantified.

[0685] The human N-terminal ELISA was designed to detect the N-terminal domain of human HRS (WHEP domain) using capture and detection antibodies that target this domain (approximately amino acids 1-60 of HRS).

[0686] Using 96-well multi-array plates coated with capture antibodies, the ELISA assay was performed following a standard Meso Scale Diagnostics ELISA protocol and using the following reagents:

[0687] · Blocking buffer: Casein (Thermo Scientific #37528)

[0688] Wash buffer: PBST (1X PBS with 0.05% Tween-20; prepared in-house)

[0689] · Diluent: 1% BSA (diluted in PBS) and casein

[0690] Capture antibody: ATYR12H6, mouse monoclonal antibody

[0691] ·Capture antibody concentration: 1μg / mL

[0692] ·Protein standard ran...

example 1

[0826] Initial Receptor Identification Screening

[0827]To identify potential interacting partners of HRS and related HRS polypeptides, HRS-Fc fusion protein constructs were evaluated using Retrogenix cell microarray screening technology (Retrogenix Ltd., High Peak Rd, United Kingdom) ( Binding of [Fc-HRS(2-60)] to a library of approximately 4500 membrane-bound human proteins expressed individually in HEK293 cells.

[0828] Briefly, HEK293 cells were plated on glass coverslips that had been pretreated by application of discrete expression vectors to enable reverse transfection and expression of each of the 4500 membrane proteins Seed membrane proteins to generate cellular microarrays. Transfection efficiency was assessed by ZsGreen1 expression and exceeded the minimum threshold for all library members screened.

[0829] Using an Fc-tagged smaller HRS fragment provides highly sensitive detection by using an AlexaFluor 647-labeled anti-human IgG Fc antibody (AF647) as a detec...

example 2

[0838] Confirmation of binding specificity by SPR analysis and identification and use of specific epitopes

[0839] A study was performed to confirm the binding specificity of Neuropilin 2 (NRP2) to Fc-HRS(2-60) using an orthologous approach to that used in the large-scale Retrogenix screen (Example 1). In a series of experiments, Fc-HRS(2-60) and related proteins were immobilized on an SPR chip, and NRP2 and related proteins were flowed as analytes. After confirming the NRP2:Fc-HRS(2-60) interaction, the dependence on divalent cations was tested since NRP2 is known to have Ca 2+ binding site. The effect of previously characterized NRP2 ligands on the NRP2:Fc-HRS(2-60) interaction was also tested to determine whether these known ligands compete for the Fc-HRS(2-60) interaction.

[0840] In another series of experiments, a monoclonal antibody (mAb) recognizing Fc-HRS(2-60) was immobilized on an SPR chip. Fc-HRS(2-60) and NRP2 were pre-incubated and injected onto the mAb surf...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are therapies, including standalone and combination therapies, for treating neuropilin-2 (NRP2)-associated diseases and conditions, which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide.

Description

[0001] Cross References to Related Applications [0002] This application requires U.S. Provisional Application No. 62 / 703,757, filed July 26, 2018, U.S. Provisional Application No. 62 / 776,208, filed December 6, 2018, filed in 2019 pursuant to 35 U.S.C. § 119(e) Priority to U.S. Provisional Application No. 62 / 800,035, filed February 1, and U.S. Provisional Application No. 62 / 849,440, filed May 17, 2019, each of which is incorporated by reference in its entirety . [0003] Statement Regarding Sequence Listing [0004] The Sequence Listing related to this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into this specification. The name of the text file containing the sequence listing is ATYR_135_04WO_ST25.txt. Said text file is 392KB, was created on July 26, 2019, and was submitted electronically via EFS-Web. technical field [0005] Embodiments of the present disclosure relate to therapies for the treatment of Neurop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/53A61K39/395A61K45/06C12N9/00C12N9/96A61P21/00
CPCA61K45/06A61P21/00C12N9/96C12N9/93C07K2319/30C07K2319/31G01N33/574G01N33/57484A61P35/00A61K38/53A61P29/00C12Y601/01021
Inventor 克里斯托夫·伯卡特凯瑟琳·M·奥吉尔维苏珊娜·帕兹桑娜·罗森格恩考斯塔布·达塔萨米克山·杜塔
Owner ATYR PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com